Home  |  Contact

Cellosaurus SKOV3-CisR (CVCL_UI88)

[Text version]

Cell line name SKOV3-CisR
Accession CVCL_UI88
Resource Identification Initiative To cite this cell line use: SKOV3-CisR (RRID:CVCL_UI88)
Comments Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
Sequence variations Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line).
Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line).
Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line).
Disease Ovarian serous cystadenocarcinoma (NCIt: C7978)
Derived from metastatic site: Ascites.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0532 (SK-OV-3)
Sex of cell Female
Age at sampling 64Y
Category Cancer cell line
Publications

PubMed=21372221; DOI=10.1158/1078-0432.CCR-10-2289
Santiskulvong C., Konecny G.E., Fekete M., Chen K.-Y.M., Karam A., Mulholland D., Eng C., Wu H., Song M., Dorigo O.
Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
Clin. Cancer Res. 17:2373-2384(2011)

Cross-references
Other Wikidata; Q98132684
Entry history
Entry creation25-Feb-2019
Last entry update20-May-2021
Version number4